Advertisement
AXON vs BEAM
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Beam Therapeutics (BEAM) Stock Comparison
Key Takeaways
- AXON is a profitable, high-growth public safety technology company with over $2.78 billion in annual revenue, while BEAM is a clinical-stage biotechnology firm with approximately $140 million in annual revenue and no approved commercial products.
- Axon Enterprise's stock snapped a nine-year winning streak in 2025, declining roughly 4% for the year, as stretched valuations and margin compression weighed on shares despite 33.5% revenue growth.
- Beam Therapeutics has experienced sustained selling pressure in recent weeks, with shares declining approximately 27% over eight consecutive trading days in mid-July 2026, reflecting biotech sector volatility and lack of near-term revenue catalysts.
- Axon offers recurring software revenue (ARR up 41% to $1.3 billion) and expanding AI-powered products, while Beam's value hinges entirely on clinical trial outcomes and eventual regulatory approvals.
- Analyst consensus rates both stocks as "Strong Buy," yet the risk profiles are fundamentally different: Axon faces execution and margin concerns, while Beam faces binary clinical-development risk.
- For risk-averse investors seeking visible growth, Axon's established business model may hold greater appeal; for those comfortable with high-risk, high-reward biotechnology, Beam's base-editing platform represents a speculative but potentially transformative opportunity.
Introduction
Comparing AXON and BEAM is a study in contrasts — one is a dominant, revenue-generating force in public safety technology, the other a pioneering but pre-revenue biotechnology company developing next-generation genetic medicines. This stock comparison is especially relevant for investors evaluating how growth-stage companies with different maturity profiles, business models, and risk landscapes stack up in the current market environment. Whether you are a growth-oriented investor seeking exposure to law enforcement AI (artificial intelligence) or a healthcare-innovation investor tracking the evolution of base editing, understanding the relative performance and market positioning of these two names offers useful perspective.
AXON Overview and Recent Performance
Axon Enterprise, headquartered in Scottsdale, Arizona, is a leading provider of public safety technology. The company's ecosystem spans TASER energy devices, body-worn and in-car cameras, cloud-based evidence management software, and a growing suite of AI-driven tools — including Draft One, a generative AI product that writes first drafts of police reports from body-camera footage, and Axon 911, a platform integrating real-time emergency communications.
Financially, Axon delivered full-year 2025 revenue of approximately $2.78 billion, representing 33.5% year-over-year growth, with the company's Software & Services segment growing at 41%. Annual Recurring Revenue (ARR) reached $1.3 billion, also up 41%, with a net revenue retention rate of 124%. Despite this robust top-line performance, profitability metrics have come under pressure: trailing net profit margin contracted to roughly 4.5% from 18.1% a year earlier, partly reflecting acquisition costs related to Carbyne ($625 million) and Prepared, as well as tariff-related hardware margin erosion.
Axon's stock fell 4% in 2025, marking its first negative year since 2015 and ending a remarkable nine-year streak of positive annual returns. In 2026, shares have continued to decline, pressured by a significant valuation reset. The stock's price-to-sales (P/S) ratio, which expanded from roughly 4x a decade ago to over 16x, has faced downward pressure as markets recalibrate expectations around profitability. Looking ahead, Axon has guided for 27%–30% revenue growth in 2026 and set an ambitious 2028 target of $6 billion in annual revenue with approximately 28% adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) margin.
BEAM Overview and Recent Performance
Beam Therapeutics, based in Cambridge, Massachusetts, is a clinical-stage biotechnology company focused on precision genetic medicines using base editing — a proprietary technology that enables precise, single-letter changes to DNA without making double-stranded breaks. Beam's pipeline spans hematology and liver-targeted genetic disease programs, including ristoglogene autogetemcel (risto-cel) for sickle cell disease (SCD), BEAM-302 for alpha-1 antitrypsin deficiency (AATD), BEAM-301 for glycogen storage disease type 1a (GSDIa), and BEAM-304 for phenylketonuria (PKU).
For full-year 2025, Beam reported total revenues of approximately $139.7 million — a 120% increase year-over-year — driven primarily by license and collaboration revenues. The company posted a net loss of roughly $80 million for the year, a significant improvement from the prior-year loss of approximately $377 million, though the Q4 2025 profit was heavily influenced by a one-time gain. Beam ended 2025 with approximately $1.25 billion in cash, cash equivalents, and marketable securities, supplemented by a $500 million non-dilutive senior credit facility from Sixth Street, extending its cash runway into mid-2029.
Beam's stock performance tells a more turbulent story. Shares gained approximately 8.6% in 2025 — underperforming the broader biotech industry — and have faced acute selling pressure in recent weeks. As of mid-July 2026, BEAM experienced eight consecutive trading days of losses, cumulatively erasing roughly 27% of its market value and roughly $1.1 billion in market capitalization. The stock's beta of 2.18 underscores its heightened sensitivity to market swings. Key catalysts ahead include updated clinical data from the BEACON trial of risto-cel and dose-escalation data from the BEAM-302 program.
Trending AI Robots
In a market environment where rapid price swings and shifting sentiment demand constant vigilance, AI-powered trading tools have gained meaningful traction among retail and institutional traders alike. Tickeron's Trending AI Robots page curates a selection of the platform's top-performing AI trading bots — chosen from hundreds of available bots that collectively trade thousands of different tickers across diverse strategies and timeframes. These bots employ distinct trading styles, from swing trading and trend following to momentum-based and mean-reversion approaches, each with its own statistical track record, win rate, and risk profile. Only those bots demonstrating the strongest alignment with current market conditions earn a place in this curated section, making it a practical starting point for traders seeking data-driven, automated insights. Explore the Trending AI Robots to see which strategies are resonating with today's market dynamics.
Head-to-Head Comparison
Business Model and Revenue Profile. The contrast is stark. AXON operates a dual revenue model combining hardware sales (TASER devices, body cameras, fleet systems) with a rapidly expanding software and services recurring revenue stream. BEAM, by contrast, generates limited collaboration revenue and has no approved products — its entire investment thesis rests on clinical pipeline success and eventual commercialization.
Growth Drivers. Axon's growth is propelled by AI product adoption, international expansion, entry into commercial markets (such as its landmark deal with a package delivery company), and strategic acquisitions. Beam's growth narrative depends on regulatory milestones — including a planned Biologics License Application (BLA) for risto-cel by the end of 2026 — and the broader validation of base editing as a therapeutic modality.
Risk Factors. Axon faces margin compression from tariffs and product mix shifts, rich valuation multiples, and persistent insider selling (CEO Patrick Smith sold over 580,000 shares across 11 transactions in an 18-month window). Beam faces binary clinical-trial risk, potential dilution to fund operations, and intense competition in both gene editing and SCD treatment markets. Beam's operating margin of approximately -226% highlights the scale of its pre-commercial spending.
Market Sentiment. Axon carries a consensus "Strong Buy" with 14 of 20 analysts rating it "Strong Buy" and a mean price target implying roughly 67% upside from recent levels. Beam also holds a "Strong Buy" consensus from 16 analysts with a mean target near $51, suggesting potential upside of over 85% — though biotech price targets carry wider uncertainty bands given binary pipeline outcomes.
Sector Exposure. Axon straddles aerospace/defense and enterprise SaaS (software-as-a-service), providing some diversification. Beam is pure-play biotechnology, meaning sector rotations and risk-off sentiment can disproportionately impact its share price.
Tickeron AI Verdict
Based on observable factors — including trend consistency, business-model visibility, revenue growth quality, and relative market positioning — Tickeron's AI would likely favor AXON in the current environment. Axon's combination of 30%-plus organic revenue growth, a $1.3 billion ARR SaaS base with 124% net retention, and a defined path toward margin expansion provides a more quantifiable and trend-consistent framework for AI-driven analysis. While BEAM offers compelling upside potential based on its base-editing platform and upcoming catalysts, its recent price action — including sustained multi-day declines and a beta above 2.0 — suggests higher levels of instability that AI models typically weigh against when evaluating risk-adjusted positioning. That said, a shift in clinical momentum or a positive regulatory catalyst could meaningfully alter this probabilistic assessment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a Hold and BEAM is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileBEAM’s FA Score has 1 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- BEAM’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while BEAM’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- BEAM’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -1.56% price change this week, while BEAM (@Biotechnology) price change was -8.83% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -0.19%. For the same industry, the average monthly price growth was -8.76%, and the average quarterly price growth was -10.50%.
The average weekly price growth across all stocks in the @Biotechnology industry was -4.78%. For the same industry, the average monthly price growth was -3.76%, and the average quarterly price growth was +1901.89%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
BEAM is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Aerospace & Defense (-0.19% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (-4.78% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | BEAM | AXON / BEAM | |
| Capitalization | 40.5B | 2.58B | 1,569% |
| EBITDA | 320M | -349.25M | -92% |
| Gain YTD | -11.549 | -9.452 | 122% |
| P/E Ratio | 202.56 | N/A | - |
| Revenue | 2.98B | 164M | 1,819% |
| Total Cash | 737M | 1.21B | 61% |
| Total Debt | 1.83B | 251M | 728% |
AXON | BEAM | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 25 Undervalued | |
PROFIT vs RISK RATING 1..100 | 64 | 100 | |
SMR RATING 1..100 | 81 | 93 | |
PRICE GROWTH RATING 1..100 | 49 | 63 | |
P/E GROWTH RATING 1..100 | 35 | 100 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BEAM's Valuation (25) in the null industry is somewhat better than the same rating for AXON (87) in the Biotechnology industry. This means that BEAM’s stock grew somewhat faster than AXON’s over the last 12 months.
AXON's Profit vs Risk Rating (64) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew somewhat faster than BEAM’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as BEAM (93) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
AXON's Price Growth Rating (49) in the Biotechnology industry is in the same range as BEAM (63) in the null industry. This means that AXON’s stock grew similarly to BEAM’s over the last 12 months.
AXON's P/E Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for BEAM (100) in the null industry. This means that AXON’s stock grew somewhat faster than BEAM’s over the last 12 months.
| AXON | BEAM | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 59% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 75% | 3 days ago 81% |
| Momentum ODDS (%) | 3 days ago 70% | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 77% | 3 days ago 90% |
| TrendWeek ODDS (%) | 3 days ago 68% | 3 days ago 83% |
| TrendMonth ODDS (%) | 3 days ago 73% | 3 days ago 82% |
| Advances ODDS (%) | 3 days ago 74% | about 1 month ago 76% |
| Declines ODDS (%) | 5 days ago 70% | 3 days ago 84% |
| BollingerBands ODDS (%) | 3 days ago 70% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 75% | 3 days ago 73% |
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | +2.12% | ||
| TECH - AXON | 61% Loosely correlated | -0.24% | ||
| VCYT - AXON | 58% Loosely correlated | -2.19% | ||
| BEAM - AXON | 57% Loosely correlated | -3.13% | ||
| SEER - AXON | 56% Loosely correlated | -3.90% | ||
| ADPT - AXON | 56% Loosely correlated | -0.18% | ||
More | ||||
BEAM and
Correlation & Price change
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | -3.13% | ||
| CRSP - BEAM | 74% Closely correlated | -2.08% | ||
| PRME - BEAM | 64% Loosely correlated | -0.67% | ||
| EDIT - BEAM | 62% Loosely correlated | -4.76% | ||
| NTLA - BEAM | 60% Loosely correlated | -3.33% | ||
| AXON - BEAM | 57% Loosely correlated | +2.12% | ||
More | ||||